# A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)

> **NCT07640217** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Adult Participants With Elevated Lipoprotein(a)

## Interventions

- **DRUG:** SYH2068 Dose 1
- **DRUG:** SYH2068 Dose 2
- **DRUG:** SYH2068 Dose 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07640217
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640217, "A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*